Therefore, ramucirumab plus paclitaxel as switch maintenance or early second-line therapy for patients with HER2-negative GC who have received standard fluoropyrimidine combined with a platinum-based chemotherapy induction deserves further study. Here, ERBB2 is linked to gastric cancer.